Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
BMJ Open. 2023 Mar 17;13(3):e069688. doi: 10.1136/bmjopen-2022-069688.
The Swedish InfCareHIV cohort was established in 2003 to ensure equal and effective care of people living with HIV (PLHIV) and enable long-term follow-up. InfCareHIV functions equally as a decision support system as a quality registry, ensuring up-to-date data reported in real time.
InfCareHIV includes data on >99% of all people with diagnosed HIV in Sweden and up to now 13 029 have been included in the cohort. InfCareHIV includes data on HIV-related biomarkers and antiretroviral therapies (ART) and also on demographics, patient-reported outcome measures and patient-reported experience measures.
Sweden was in 2015 the first country to reach the UNAIDS (United Nations Programme on HIV/AIDS)/WHO's 90-90-90 goals. Late diagnosis of HIV infection was identified as a key problem in the Swedish HIV-epidemic, and low-level HIV viraemia while on ART associated with all-cause mortality. Increased HIV RNA load in the cerebrospinal fluid (CSF) despite suppression of the plasma viral load was found in 5% of PLHIV, a phenomenon referred to as 'CSF viral escape'. Dolutegravir-based treatment in PLHIV with pre-existing nucleoside reverse transcriptase inhibitor-mutations was non-inferior to protease inhibitor-based regimens. An increase of transmitted drug resistance was observed in the InfCareHIV cohort. Lower efficacy for protease inhibitors was not due to lower adherence to treatment. Incidence of type 2 diabetes and insulin resistance was high in the ageing HIV population. Despite ART, the risk of infection-related cancer as well as lung cancer was increased in PLHIV compared with HIV-negative. PLHIV were less likely successfully treated for cervical precancer and more likely to have human papillomavirus types not included in current HPV vaccines. Self-reported sexual satisfaction in PLHIV is improving and is higher in women than men.
InfCareHIV provides a unique base to study and further improve long-term treatment outcomes, comorbidity management and health-related quality of life in people with HIV in Sweden.
瑞典 InfCareHIV 队列于 2003 年成立,旨在确保艾滋病毒感染者(PLHIV)获得平等有效的治疗,并实现长期随访。InfCareHIV 既是决策支持系统,也是质量登记系统,确保实时报告最新数据。
InfCareHIV 包含瑞典所有诊断为 HIV 的人群中超过 99%的数据,迄今为止已有 13029 人纳入该队列。InfCareHIV 包含与 HIV 相关的生物标志物和抗逆转录病毒疗法(ART)的数据,以及人口统计学数据、患者报告的结局测量指标和患者报告的体验测量指标。
瑞典是 2015 年第一个达到联合国艾滋病规划署(UNAIDS)/世界卫生组织 90-90-90 目标的国家。HIV 感染的晚期诊断被确定为瑞典 HIV 流行中的一个关键问题,而 ART 期间低水平的 HIV 病毒血症与全因死亡率相关。尽管血浆病毒载量得到抑制,但仍有 5%的 PLHIV 出现脑脊液(CSF)中 HIV RNA 载量增加的现象,这种现象被称为“CSF 病毒逃逸”。在预先存在核苷逆转录酶抑制剂突变的 PLHIV 中,基于多替拉韦的治疗与基于蛋白酶抑制剂的方案相当。在 InfCareHIV 队列中观察到传播耐药性的增加。蛋白酶抑制剂疗效降低并不是由于治疗依从性降低所致。随着 HIV 人群年龄的增长,2 型糖尿病和胰岛素抵抗的发生率很高。与 HIV 阴性人群相比,PLHIV 感染相关癌症和肺癌的风险增加。尽管进行了 ART,PLHIV 感染相关癌症和肺癌的风险仍增加。PLHIV 接受宫颈癌前病变治疗的成功率较低,且更有可能感染当前 HPV 疫苗未涵盖的 HPV 类型。PLHIV 的自我报告性满意度正在提高,女性高于男性。
InfCareHIV 为研究和进一步改善瑞典 HIV 感染者的长期治疗结果、合并症管理和健康相关生活质量提供了独特的基础。